<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Observational studies assessing the association of combination therapy of <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> on <z:hpo ids='HP_0000001'>all</z:hpo>-cause and/or cardiovascular mortality in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> have shown conflicting results </plain></SENT>
<SENT sid="1" pm="."><plain>We therefore evaluated the effects of combination therapy of <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi> on the risk of <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) among people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: A MEDLINE search (January 1966-July 2007) was conducted to identify observational studies that examined the association between combination therapy of <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi> on risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> or <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality </plain></SENT>
<SENT sid="3" pm="."><plain>From 299 relevant reports, 9 were included in the meta-analysis </plain></SENT>
<SENT sid="4" pm="."><plain>In these studies, combination therapy of <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> was assessed, the risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> and/or mortality was reported, and adjusted relative risk (RR) or equivalent (hazard ratio and odds ratio) and corresponding variance or equivalent was reported </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The pooled RRs (95% CIs) of outcomes for individuals with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> prescribed combination therapy of <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi> were 1.19 (0.88-1.62) for <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality, 1.29 (0.73-2.27) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> mortality, and 1.43 (1.10-1.85) for a composite end point of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> hospitalizations or mortality (fatal or nonfatal events) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: The combination therapy of <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> significantly increased the RR of the composite end point of cardiovascular hospitalization or mortality (fatal and nonfatal events) irrespective of the reference group (diet therapy, <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy, or <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> monotherapy); however, there were no significant effects of this combination therapy on either <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> mortality or <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality alone </plain></SENT>
</text></document>